Completed

Chitosan Oligosaccharide's Impact on Post Prandial Glucose Control in Normal to Impaired Glucose Tolerance Individuals

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being tested

Chitosan Oligosaccharide (GO2KA1)

+ White egg

Dietary Supplement
Who is being recruted

Diabetes Mellitus+4

+ Endocrine System Diseases

+ Hyperglycemia

From 20 to 74 Years
+13 Eligibility Criteria
See all eligibility criteria
How is the trial designed

Treatment Study

Placebo-Controlled
Interventional
Study Start: May 2018
See protocol details

Summary

Principal SponsorYonsei University
Last updated: January 27, 2026
Sourced from a government-validated database.Claim as a partner

Study start date: May 9, 2018

Actual date on which the first participant was enrolled.

This is a study about a substance called chitosan oligosaccharide (GO2KA1) and how it might help control blood sugar levels after eating in people with normal blood glucose, impaired fasting glucose, and impaired glucose tolerance. The study involves healthy male and female participants aged 20-75 years. It's important because it could help find new ways to manage blood sugar levels, which is a key challenge in conditions like prediabetes and diabetes. In this study, participants visit the research site twice, with a seven-day interval. On the first visit, they are given either the test product (GO2KA1) or a placebo (white egg powder), and on the second visit, they receive the other product. On both visits, a 2-hr oral sucrose tolerance test is conducted in the morning, and blood samples are collected before and after they consume the product. The main goal is to compare the differences in blood glucose levels during this test between the GO2KA1 and the placebo.

Official TitleA Crossover Trial of Chitosan Oligosaccharide (GO2KA1) on Post Prandial Glucose Control in Subjects With Normal Blood Glucose, Impaired Fasting Glucose and Impaired Glucose Tolerance
NCT03650023
Principal SponsorYonsei University
Last updated: January 27, 2026
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

37 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Treatment Study

These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.

Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

From 20 to 74 Years

Range of ages for which participants are eligible to join.

Healthy volunteers allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Diabetes MellitusEndocrine System DiseasesHyperglycemiaMetabolic DiseasesNutritional and Metabolic DiseasesGlucose IntoleranceGlucose Metabolism Disorders

Criteria

3 inclusion criteria required to participate
Normal Blood Glucose (fasting blood sugar below 100mg/dl, two hours after meals below 140mg/dl)
Impaired Fasting Glucose (fasting blood sugar 100-125mg/dl)
Impaired Glucose Tolerance (two hours after meals 140-199mg/dl)
10 exclusion criteria prevent from participating
history/presence of diabetes mellitus (including oral hypoglycaemic agent and insulin)
history of serious hypoglycemia
history of serious cardiovascular, cerebrovascular disease, pulmonary, gastrointestinal, hepatic, renal and/or haematological disease
uncontrolled blood pressure (blood pressure level more than 140/90mmHg)
Show More Criteria

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.
Treatment Groups
Study Objectives

2 intervention groups are designated in this study

50% chance of being blinded to the placebo group

Treatment Groups

Group I

Experimental
Chitosan Oligosaccharide (GO2KA1) capsule was provided to the study participants. The Chitosan Oligosaccharide (GO2KA1) capsule was consumed within 15 min, and then 2-h oral sucrose tolerance test was conducted. The Chitosan Oligosaccharide (GO2KA1) one capsule had Chitosan Oligosaccharide 250mg.

Group II

Placebo
White egg capsule was provided to the study participants. The White egg capsule was consumed within 15 min, and then 2-h oral sucrose tolerance test was conducted. The Chitosan Oligosaccharide (GO2KA1) one capsule had White egg 250mg.

Study Objectives

Primary Objectives

Secondary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 1 location

Suspended

Laboratory of Clinical Nutrigenetics/Nutrigenomics, Yonsei University.

Seoul, South KoreaOpen Laboratory of Clinical Nutrigenetics/Nutrigenomics, Yonsei University. in Google Maps
CompletedOne Study Center